Pulse Biosciences (NASDAQ:PLSE) Hits New 52-Week High – Here’s What Happened

Pulse Biosciences, Inc (NASDAQ:PLSE) shares reached a new 52-week high on Thursday . The company traded as high as $46.03 and last traded at $46.75, with a volume of 88698 shares changing hands. The stock had previously closed at $43.32.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on PLSE shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a report on Friday, July 17th. Oppenheimer reissued an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Mizuho set a $45.00 target price on shares of Pulse Biosciences in a research note on Monday. Wall Street Zen downgraded shares of Pulse Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Finally, Canaccord Genuity Group lifted their target price on shares of Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a report on Monday. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $41.00.

Pulse Biosciences Trading Up 4.3%

The stock has a market cap of $3.13 billion, a P/E ratio of -38.28 and a beta of 1.61. The firm has a 50-day simple moving average of $30.12 and a two-hundred day simple moving average of $24.32.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 100.22%. The business had revenue of $0.43 million during the quarter, compared to analyst estimates of $0.53 million. Sell-side analysts predict that Pulse Biosciences, Inc will post -1.29 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in PLSE. Russell Investments Group Ltd. increased its holdings in Pulse Biosciences by 13.8% in the 4th quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock valued at $70,000 after buying an additional 619 shares during the period. BNP Paribas Financial Markets grew its holdings in Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after acquiring an additional 680 shares during the last quarter. Alliancebernstein L.P. raised its position in Pulse Biosciences by 6.7% during the 3rd quarter. Alliancebernstein L.P. now owns 20,620 shares of the company’s stock worth $365,000 after purchasing an additional 1,300 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Pulse Biosciences by 275.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after buying an additional 2,156 shares during the period. Finally, Barclays PLC increased its position in Pulse Biosciences by 8.5% during the 4th quarter. Barclays PLC now owns 27,652 shares of the company’s stock valued at $380,000 after purchasing an additional 2,164 shares during the period. 76.95% of the stock is owned by institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.